Pure Global AI
NCT06212102Not yet recruiting

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial
Bedaya HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Infertility
Drug/Device/Intervention
Progestin primed ovarian stimulation
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Bedaya Hospital
Location
Giza, Egypt
Timeline & enrollment
Phase
Phase 2
Start date
Feb 01, 2024
End date
Dec 01, 2026
Enrollment
120 participants
Primary outcome

Medications costs per retrieved oocyte

Summary

The aim of this randomized controlled trial was to compare the efficacy and
 cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in
 poor responders undergoing double stimulation protocol.

ICD-10 classifications
Female infertilityMale infertilityFemale infertility, unspecifiedFemale infertility of other originFemale infertility of uterine origin
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06212102
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06212102 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bedaya Hospital and is currently Not yet recruiting. The study focuses on Infertility. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.